Background Aggressive primary brain tumors such as glioblastoma are uniquely
challenging to treat. The intracranial location poses barriers to therapy, and the potential for …

Glioblastoma is the most malignant primary brain tumor and is still in need of effective
medical treatment. We isolated patient-derived glioblastoma cells showing high GD2 …

Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary brain
tumor in adults. Current treatment options typically consist of surgery followed by …

Glioblastoma (GBM) is a highly aggressive glioma with an extremely poor prognosis after
conventional treatment. Recent advances in immunotherapy offer hope for these patients …

Purpose: A delay in encountering the cognate antigen while in the circulation, and the
suboptimal costimulation received at the tumor site are key reasons for the limited activity of …

T cell immunotherapy is emerging as a powerful strategy to treat cancer and may improve
outcomes for patients with glioblastoma (GBM). We have developed a chimeric antigen …

Purpose: Glioblastoma multiforme (GBM) remains highly incurable, with frequent
recurrences after standard therapies of maximal surgical resection, radiation, and …

Gliomas are highly treatment refractory against immune checkpoint blockade, an
immunotherapeutic modality that revolutionized therapy for many tumors. At the same time …

Purpose: Elevated proportions of regulatory T cells (Treg) are present in patients with a
variety of cancers, including malignant glioma, yet recapitulative murine models are wanting …

In order to fully harness the potential of immunotherapy with chimeric antigen receptor
(CAR)-modified T cells, pre-clinical studies must be conducted in immunocompetent animal …